| Date | Title | Description | |
|---|---|---|---|
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
| 21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
| 21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 07 Nov 2024 | On P&L | A correction to the English version of a document is reported. | Download |
| 03 Oct 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2024 | Download |
| 12 Sep 2024 | Other relevant information | The Company announces the registration in the Commercial Registry of the public deed of reduction of its share capital and the new share capital figure. | Download |
| 01 Aug 2024 | Other relevant information | The Company has agreed to execute the share capital reduction approved by the 2024 Ordinary General Meeting to amortize treasury shares, among which those acquired in the framework of the own shares repurchase program. | Download |
| 31 Jul 2024 | Liquidity and counterparty agreements | Modification of securities and cash balances associated with the Liquidity Contract signed between the Company and Bestinver, S.V., S.A. | Download |